Back

Temporal changes in echocardiographic parameters of diastolic dysfunction in obstructive hypertrophic cardiomyopathy during mavacamten treatment

19 May 2025 (13:00 - 14:00)
Organised by: Logo
Congress Presentation Part of: ePosters in myocardial disease - hypertrophic cardiomyopathy (3) Hypertrophic Cardiomyopathy HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Hedvig Takacs

University of Szeged, Szeged (Hungary)

7 More presentations in this session

Presentation thumbnail
Mavacamten eligibility in an Irish hypertrophic cardiomyopathy cohort
Mr P. Kopp (Stony Brook, US)
Abstract Slides Video
Presentation thumbnail
Usefulness of implantable loop recorders in patients with hypertrophic cardiomyopathy
Doctor M. Figueiredo (Barreiro, PT)
Abstract Slides Video
Presentation thumbnail
Medical education significantly improves the recognition of red flags of transthyretin cardiac amyloidosis
Doctor C. Rohani-Montez (London, GB)
Abstract Slides Video
Presentation thumbnail
Reduction of >100 mmHg left ventricular outflow tract gradients in obstructive hypertrophic cardiomyopathy during mavacamten treatment already after one week of treatment
Doctor R. Sepp (Szeged, HU)
Abstract Slides Video
Presentation thumbnail
Phenotypic expression and prognostic determinants in TPM1-associated hypertrophic cardiomyopathy: insights from a tertiary center cohort
Doctor C. Gregorio (Lisbon, PT)
Abstract Slides Video

Access the full session

Session thumbnail
ePosters in myocardial disease - hypertrophic cardiomyopathy (3)

The Event

Event poster

Heart Failure 2025

19 May 2025 13:00 CET
You may be interested in
thumbnail
Congress Presentation
Effect of Mavacamten on left ventricular diastolic function and left atrial function in obstructive hypertrophic cardiomyopathy
thumbnail
Congress Presentation
Evaluation of cardiac MRI parameters during mavacamten treatment in obstructive hypertrophic cardiomyopathy: three- and six-month results
thumbnail
Congress Presentation
Change of 3D echocardiographic parameters in obstructive hypertrophic cardiomyopathy during mavacamten treatment

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources